Poulton Jeffrey V. 4
4 · ALNYLAM PHARMACEUTICALS, INC. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Alnylam (ALNY) CFO Jeffrey V. Poulton Sells Shares
What Happened
Jeffrey V. Poulton, Chief Financial Officer of Alnylam Pharmaceuticals (ALNY), disposed of 2,468 shares in a series of open‑market sales on March 4, 2026, generating total proceeds of approximately $797,349. The sales were reported as multiple transactions with weighted average prices ranging roughly from $318.27 to $326.21 (individual reported weighted prices included $319.03, $320.01, $320.81, $321.82, $323.01, $323.84, $324.88 and $325.67). According to the filing, these disposals were made pursuant to a mandatory sell‑to‑cover provision to satisfy minimum statutory tax withholding on vested restricted stock units (RSUs) — a routine, tax‑related sale rather than an opportunistic open‑market trade.
Key Details
- Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (filed within the normal two‑business‑day window).
- Breakdown (shares @ price = proceeds): 114 @ $319.03 = $36,369; 109 @ $320.01 = $34,881; 230 @ $320.81 = $73,786; 309 @ $321.82 = $99,442; 374 @ $323.01 = $120,806; 818 @ $323.84 = $264,901; 291 @ $324.88 = $94,540; 223 @ $325.67 = $72,624. Total: 2,468 shares for ~$797,349.
- Primary footnote: F1 — shares automatically sold by the company on behalf of the reporting person under a mandatory sell‑to‑cover provision to cover tax withholding on vested RSUs.
- Other footnotes in the filing (F2–F9) explain that reported prices are weighted averages across multiple transactions within given price ranges; F10 notes shares acquired under the issuer 401(k) matching program (separate item).
- Shares owned after the transactions are not specified in the provided excerpt of the filing.
Context: These sales were executed to satisfy tax withholding on vested RSUs (routine, indicated by the sell‑to‑cover footnote) and therefore are generally considered administrative rather than a market sentiment signal. For investors tracking insider activity, purchases tend to be more informative about confidence; routine sell‑to‑cover transactions are common when equity awards vest.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-03-04$319.03/sh−114$36,369→ 64,159 total - Sale
Common Stock
[F1][F3]2026-03-04$320.01/sh−109$34,881→ 64,050 total - Sale
Common Stock
[F1][F4]2026-03-04$320.81/sh−230$73,786→ 63,820 total - Sale
Common Stock
[F1][F5]2026-03-04$321.82/sh−309$99,442→ 63,511 total - Sale
Common Stock
[F1][F6]2026-03-04$323.01/sh−374$120,806→ 63,137 total - Sale
Common Stock
[F1][F7]2026-03-04$323.84/sh−818$264,901→ 62,319 total - Sale
Common Stock
[F1][F8]2026-03-04$324.88/sh−291$94,540→ 62,028 total - Sale
Common Stock
[F1][F9]2026-03-04$325.67/sh−223$72,624→ 61,805 total
- 57(indirect: by Managed Account)
Common Stock
[F10]
Footnotes (10)
- [F1]Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
- [F10]Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
- [F2]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F4]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F5]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F6]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F7]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F8]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F9]The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.